Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2026)

Amneal Pharmaceuticals has reported Invested Capital for 10 years, with the latest figure at $2.7 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 14.79% year-over-year to $2.7 billion in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 14.79% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, changed 0.26% from the prior year.
• Invested Capital was $2.7 billion for Q2 2026 at Amneal Pharmaceuticals, up from $2.5 billion in the prior quarter.
• The five-year high for Invested Capital was $3.1 billion in Q1 2022, with the low at $2.3 billion in Q1 2025.
• Average Invested Capital over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Invested Capital dropped 11.07% in 2024, then advanced 14.79% in 2026.
• Over 5 years, Invested Capital stood at $2.9 billion in 2022, then decreased by 8.69% to $2.6 billion in 2023, then declined by 4.52% to $2.5 billion in 2024, then gained by 0.26% to $2.5 billion in 2025, then increased by 7.82% to $2.7 billion in 2026.
• The last three Invested Capital figures came in at $2.7 billion (Q2 2026), $2.5 billion (Q1 2026), and $2.5 billion (Q4 2025), per Business Quant data.